MedTrace Logo

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

NCT04569916 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-09-30

No results posted yet for this study

Summary

An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.

Conditions

Interventions

RADIATION

radiotherapy

radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

DRUG

irinotecan liposome

radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

DRUG

apatinib

radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

DRUG

PD-1 antibody

radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    lead OTHER

Principal Investigators

  • Baorui Baorui Liu, Doctor · Nanjing Drum Tower Hospital, The Affiliated of Nanjing University Medical School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2023-02-28
Completion
2023-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04569916 on ClinicalTrials.gov